Redux Bio develops RNA interference (RNAi) products that silence essential genes in bacterial, viral, and parasitic pathogens, providing a non‑antibiotic, species‑specific disease‑prevention solution for livestock and aquaculture. The formulations are designed for oral delivery through feed or water, allowing seamless integration into existing husbandry practices while reducing disease incidence and antimicrobial resistance.
Funding
Funding not disclosed
Founders
Product
Problem
Livestock and aquaculture producers rely heavily on antibiotics to control infectious diseases, contributing to antimicrobial resistance and limiting sustainable disease‑prevention options. Existing preventative tools are often ineffective against emerging pathogens, leading to higher mortality, reduced productivity, and increased regulatory pressure.
Solution
Redux Bio leverages RNA interference (RNAi) to develop a platform of preventative animal‑health products that silence pathogen‑specific genes before infection takes hold. The technology is formulated for oral delivery via feed or water, enabling seamless integration into standard husbandry practices without the need for injections or veterinary visits. By targeting the genetic machinery of bacteria, viruses, or parasites, the products provide a species‑specific, non‑antibiotic approach that reduces disease incidence and limits the spread of resistance. The platform is designed for both terrestrial livestock (e.g., swine, poultry, cattle) and aquatic species, addressing unmet needs across the animal‑protein supply chain. Redux Bio’s pipeline follows a regulated development pathway, with scalable biomanufacturing processes that support commercial‑grade production and consistent product quality.
Target Audience
Primary customers are commercial livestock and aquaculture producers, as well as veterinary service providers seeking antibiotic‑free disease‑prevention solutions for their herds and fish stocks.
Features
- RNAi‑based active ingredients that selectively silence essential genes in target pathogens, offering a precision‑medicine approach to disease prevention.
- Feed‑ and water‑compatible formulations that can be administered through existing delivery systems, minimizing operational disruption.
- Broad applicability across multiple species, including cattle, swine, poultry, and finfish, with customizable sequences for specific disease challenges.
- Scalable microbial fermentation and downstream purification processes that meet GMP standards and enable cost‑effective large‑volume production.
- Comprehensive safety and efficacy data packages aligned with FDA/EMA veterinary regulatory requirements, facilitating faster market entry.
- Integrated digital monitoring tools that track dosage compliance and health outcomes, supporting data‑driven herd or farm management.
- Environmentally sustainable manufacturing footprint, reducing reliance on synthetic antibiotics and associated waste streams.